|
| Press Releases |
|
 |
|
| Saturday, August 24, 2024 |
|
|
日本厚生勞動省批准了莫德納公司針對SARS-COV-2 JN.1變異株的COVID-19 mRNA疫苗的部分變更申請 |
| Moderna, Inc.（納斯達克股票代碼：MRNA）今日宣佈，已獲得日本厚生勞動省（MHLW）批准其COVID-19 mRNA疫苗Spikevax更新配方的部分變更申請，該疫苗針對SARS-CoV-2 JN.1變異株。 more info >> |
|
|
日本厚生劳动省批准了莫德纳公司针对SARS-COV-2 JN.1变异株的COVID-19 mRNA疫苗的部分变更申请 |
| Moderna, Inc.（纳斯达克股票代码：MRNA）今日宣布，已获得日本厚生劳动省（MHLW）批准其COVID-19 mRNA疫苗Spikevax更新配方的部分变更申请，该疫苗针对SARS-CoV-2 JN.1变异株。 more info >> |
|
|
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1 |
| Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1. more info >> |
|
| Tuesday, March 26, 2024 |
|
|
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine |
| Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine. more info >> |
|
| Monday, December 11, 2023 |
|
|
Moderna公司回顧了在第二次環境、社會和治理（ESG）投資者活動中取得的進展和雄心 |
| more info >> |
|
|
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event |
| more info >> |
|
| Wednesday, July 5, 2023 |
|
|
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345 |
| Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older. more info >> |
|
| Wednesday, May 3, 2023 |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
|
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines |
| Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced plans to establish an Enterprise Solutions Hub in the Philippines. The Moderna Enterprise Solutions Hub will provide business services across the Asia Pacific region, where Moderna currently has operations in six markets. Moderna also plans to establish commercial operations in the Philippines. more info >> |
|
| Tuesday, September 13, 2022 |
|
|
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines |
| PT Bio Farma, the holding company for state-owned pharmaceutical companies in Indonesia, announced a new milestone in manufacturing IndoVac, a Covid-19 vaccine brand it has developed since November 2021. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
在 2026 年 Gartner(R)《供應鏈規劃解決方案：流程工業》魔力象限(TM) 報告中，OMP 在「願景完整性」與「執行能力」兩大指標上均位居首位
Mar 23, 2026 23:15 HKT/SGT
|
|
|
在2026年Gartner(R)《供应链规划解决方案魔力象限(TM)：流程工业》报告中，OMP在“愿景完整性”和“执行能力”两项指标上均位居最高位置
Mar 23, 2026 23:15 HKT/SGT
|
|
|
OMP Positioned Highest for Both Completeness of Vision and Ability to Execute in the 2026 Gartner(R) Magic Quadrant(TM) for Supply Chain Planning Solutions: Process Industries
Mar 23, 2026 23:15 HKT/SGT
|
|
|
Wellgistics Health Inc. 簽署價值 1.05 億美元的意向書，以評估收購 Neuritek Therapeutics, Inc. 的可能性；該公司致力於開發治療神經系統及精神疾病的創新療法
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Wellgistics Health Inc.签署1.05亿美元意向书，拟评估收购Neuritek Therapeutics, Inc.的可行性，后者致力于开发神经系统及精神疾病的创新疗法
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Mar 23, 2026 21:05 HKT/SGT
|
|
|
Essex Bio-Technology Reports Robust Results for FY2025, Turnover Soars 8.6% to HK$1814 million, Net Profit up 3.5% to HK$ 318.1 million, Total Dividend Increases by 16.7% to HK14 Cents per Share
Mar 23, 2026 20:51 HKT/SGT
|
|
|
億勝生物科技2025全年業績穩健 收入升8.6%至18.14億港元 淨利潤升3.5%至3.18億港元 全年股息增加16.7%至每股14港仙
Mar 23, 2026 20:37 HKT/SGT
|
|
|
GMG Launches European Sales Team; G(R) Lubricant Patent Accepted for Europe
Mar 23, 2026 20:29 HKT/SGT
|
|
|
亿胜生物科技2025全年业绩稳健 收入升8.6%至18.14亿港元 净利润升3.5%至3.18亿港元 全年股息增加16.7%至每股14港仙
Mar 23, 2026 20:13 HKT/SGT
|
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint
Mar 23, 2026 18:59 HKT/SGT
|
|
|
雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局
Mar 23, 2026 18:59 HKT/SGT
|
|
|
云顶新耀达成艾曲帕米鼻喷雾剂资产收购协议 强化心血管领域产品布局
Mar 23, 2026 18:59 HKT/SGT
|
|
|
同仁堂医养（02667.HK）新股招股：尚在发展早期的中医医疗龙头股 估值几何？
Mar 23, 2026 16:21 HKT/SGT
|
|
|
同仁堂醫養（02667.HK）新股招股：尚在發展早期的中醫醫療龍頭股 估值幾何？
Mar 23, 2026 16:21 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
